CytoMed Therapeutics shares are trading higher after the company announced that its subsidiary, IPSC Depository, acquired the license and certain assets of Cellsafe International for approximately $490,000 to be funded from internal cash resources.

7/17/24 8:02:15 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $GDTC alert in real time by email

Get the next $GDTC alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$GDTC

Date	Price Target	Rating	Analyst

More analyst ratings

$GDTC
Press Releases

Fastest customizable press release news feed in the world

Update on Clinical Milestone - CytoMed Therapeutics Announces First Patient Dosed in its First-in-Human Phase I Clinical Trial of Allogeneic CAR-Gamma Delta T Cell Therapy in Patients with Advanced Solid Tumours or Haematological Malignancies
SINGAPORE, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Further to an announcement on October 7, 2024, CytoMed Therapeutics Limited (NASDAQ:GDTC) ("CytoMed" or "Company"), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor blood-derived, cell-based allogeneic therapies for the treatment of blood and solid cancers, is pleased to announce that the first patient has been dosed in its first-in-human Phase I dose-escalation clinical trial (NCT05302037) ("ANGELICA Trial"). This trial has been registered with and has received clinical trial authorisation from the Health Sciences Authority in Singapore. The ANGELICA Trial evaluates allogenei
11/20/24 7:00:00 AM ET
$GDTC
Biotechnology: Pharmaceutical Preparations
Health Care
CytoMed Therapeutics' first-in-human Phase I ANGELICA clinical trial using its patented donor allogeneic chimeric antigen receptor T cell (CAR-T cell) against blood and solid tumors received co-funding support from the NMRC Clinical Trial Grant
SINGAPORE, Oct. 07, 2024 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ:GDTC) ("CytoMed" or the "Company"), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor blood-derived, cell-based allogeneic therapies for the treatment of various cancers including blood and solid cancers has obtained full approval for its first-in-human Phase I clinical trial ("ANGELICA Trial") using its patented allogeneic chimeric antigen receptor T cell ("CAR-T cell") against several blood and solid tumors in collaboration with the National University Hospital ("NUH") of Singapore. The ANGELICA Trial is co-supported by the Singapore Minist
10/7/24 7:00:00 AM ET
$GDTC
Biotechnology: Pharmaceutical Preparations
Health Care
CytoMed Therapeutics completes cash acquisition of Cord Blood Banking Licence and Assets expanding CytoMed's strategy to cord blood-derived biologics through subsidiary, LongevityBank
SINGAPORE, Oct. 03, 2024 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ:GDTC) ("CytoMed" or "Company"), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor blood-derived, cell-based allogeneic therapies for the treatment of various cancers and aging-related diseases, has through its subsidiary, IPSC Depository Sdn Bhd, acquired the licence and certain assets of Cellsafe International Sdn Bhd (In Liquidation), a Malaysian cord blood bank. The acquisition includes (i) a cord blood banking licence issued by Malaysia's Ministry of Health, (ii) cryopreservation equipment with more than 12,000 cord blood units ("CBUs"
10/3/24 7:00:00 AM ET
$GDTC
Biotechnology: Pharmaceutical Preparations
Health Care

CytoMed Therapeutics' first-in-human Phase I ANGELICA clinical trial using its patented donor allogeneic chimeric antigen receptor T cell (CAR-T cell) against blood and solid tumors received co-funding support from the NMRC Clinical Trial Grant
SINGAPORE, Oct. 07, 2024 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ:GDTC) ("CytoMed" or the "Company"), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor blood-derived, cell-based allogeneic therapies for the treatment of various cancers including blood and solid cancers has obtained full approval for its first-in-human Phase I clinical trial ("ANGELICA Trial") using its patented allogeneic chimeric antigen receptor T cell ("CAR-T cell") against several blood and solid tumors in collaboration with the National University Hospital ("NUH") of Singapore. The ANGELICA Trial is co-supported by the Singapore Minist
10/7/24 7:00:00 AM ET
$GDTC
Biotechnology: Pharmaceutical Preparations
Health Care
CytoMed Therapeutics Reports Six Months Ended June 30, 2024 Financial Results and Provides Clinical and Corporate Updates
Conference call via Zoom is scheduled for October 8, 2024 at 9 a.m. ET (9 p.m. SGT) https://us06web.zoom.us/meeting/register/tZMrcOmppj0sGdA37lASywTyixRflo9w1TZT SINGAPORE, Sept. 30, 2024 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ:GDTC) ("CytoMed" or "Company"), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor-derived, cell-based allogeneic immunotherapies for the treatment of a broad range of cancers including blood and solid tumors, today announced six months ended June 30, 2024 financial results and provided clinical and corporate updates. "We are committed to advancing our "off-the-shelf" allogeneic c
9/30/24 7:00:00 AM ET
$GDTC
Biotechnology: Pharmaceutical Preparations
Health Care
CytoMed Therapeutics Acquires Cord Blood Banking Licence and Assets to Entrench Its Strategy in Allogeneic, Off-the-shelf Donor-derived Gamma Delta (γδ) T Cells Technology for Solid and Liquid Cancers
SINGAPORE, July 17, 2024 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ:GDTC) ("CytoMed" or "Company"), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor blood-derived, cell-based allogeneic therapies for the treatment of various cancers and aging-related diseases, has, through its wholly owned subsidiary, IPSC Depository Sdn Bhd acquired the licence and certain assets of Cellsafe International Sdn Bhd (In Liquidation) ("CISB"), a Malaysian cord blood bank for a cash consideration of approximately RM 2.3 million or US$ 490,000 to be funded from internal cash resources. The price consideration includes a cord blo
7/17/24 7:00:00 AM ET
$GDTC
Biotechnology: Pharmaceutical Preparations
Health Care

CytoMed Therapeutics shares are trading higher after the company announced that its subsidiary, IPSC Depository, acquired the license and certain assets of Cellsafe International for approximately $490,000 to be funded from internal cash resources.

Chat with this insight

Recent Analyst Ratings for
$GDTC

$GDTC
Leadership Updates

Live Leadership Updates

CytoMed Therapeutics completes cash acquisition of Cord Blood Banking Licence and Assets expanding CytoMed's strategy to cord blood-derived biologics through subsidiary, LongevityBank

$GDTC
Press Releases

Fastest customizable press release news feed in the world

Update on Clinical Milestone - CytoMed Therapeutics Announces First Patient Dosed in its First-in-Human Phase I Clinical Trial of Allogeneic CAR-Gamma Delta T Cell Therapy in Patients with Advanced Solid Tumours or Haematological Malignancies

CytoMed Therapeutics' first-in-human Phase I ANGELICA clinical trial using its patented donor allogeneic chimeric antigen receptor T cell (CAR-T cell) against blood and solid tumors received co-funding support from the NMRC Clinical Trial Grant

CytoMed Therapeutics completes cash acquisition of Cord Blood Banking Licence and Assets expanding CytoMed's strategy to cord blood-derived biologics through subsidiary, LongevityBank

$GDTC
Large Ownership Changes

This live feed shows all institutional transactions in real time.

$GDTC
Financials

Live finance-specific insights

SEC Form SC 13G/A filed by CytoMed Therapeutics Limited (Amendment)

CytoMed Therapeutics' first-in-human Phase I ANGELICA clinical trial using its patented donor allogeneic chimeric antigen receptor T cell (CAR-T cell) against blood and solid tumors received co-funding support from the NMRC Clinical Trial Grant

CytoMed Therapeutics Reports Six Months Ended June 30, 2024 Financial Results and Provides Clinical and Corporate Updates

CytoMed Therapeutics Acquires Cord Blood Banking Licence and Assets to Entrench Its Strategy in Allogeneic, Off-the-shelf Donor-derived Gamma Delta (γδ) T Cells Technology for Solid and Liquid Cancers

$GDTC
SEC Filings

SEC Form 6-K filed by CytoMed Therapeutics Limited

SEC Form 6-K filed by CytoMed Therapeutics Limited

SEC Form 6-K filed by CytoMed Therapeutics Limited

$GDTC
Market Insights

Live Market Insights

CytoMed Therapeutics shares are trading higher after the company announced that its subsidiary, IPSC Depository, acquired the license and certain assets of Cellsafe International for approximately $490,000 to be funded from internal cash resources.

Cytomed Therapeutics, Through Its Wholly Owned Subsidiary, IPSC Depository Acquired The Licence And Certain Assets Of Cellsafe International For A Cash Consideration Of About RM 2.3M Or $490,000 To Be Funded From Internal Cash Resources

Benchmark Reiterates Speculative Buy on CytoMed Therapeutics, Maintains $5 Price Target

CytoMed Therapeutics shares are trading higher after the company announced that its subsidiary, IPSC Depository, acquired the license and certain assets of Cellsafe International for approximately $490,000 to be funded from internal cash resources.

Chat with this insight

Recent Analyst Ratings for $GDTC

$GDTC Leadership Updates

Live Leadership Updates

CytoMed Therapeutics completes cash acquisition of Cord Blood Banking Licence and Assets expanding CytoMed's strategy to cord blood-derived biologics through subsidiary, LongevityBank

$GDTC Press Releases

Fastest customizable press release news feed in the world

Update on Clinical Milestone - CytoMed Therapeutics Announces First Patient Dosed in its First-in-Human Phase I Clinical Trial of Allogeneic CAR-Gamma Delta T Cell Therapy in Patients with Advanced Solid Tumours or Haematological Malignancies

CytoMed Therapeutics' first-in-human Phase I ANGELICA clinical trial using its patented donor allogeneic chimeric antigen receptor T cell (CAR-T cell) against blood and solid tumors received co-funding support from the NMRC Clinical Trial Grant

CytoMed Therapeutics completes cash acquisition of Cord Blood Banking Licence and Assets expanding CytoMed's strategy to cord blood-derived biologics through subsidiary, LongevityBank

$GDTC Large Ownership Changes

This live feed shows all institutional transactions in real time.

$GDTC Financials

Live finance-specific insights

SEC Form SC 13G/A filed by CytoMed Therapeutics Limited (Amendment)

CytoMed Therapeutics' first-in-human Phase I ANGELICA clinical trial using its patented donor allogeneic chimeric antigen receptor T cell (CAR-T cell) against blood and solid tumors received co-funding support from the NMRC Clinical Trial Grant

CytoMed Therapeutics Reports Six Months Ended June 30, 2024 Financial Results and Provides Clinical and Corporate Updates

CytoMed Therapeutics Acquires Cord Blood Banking Licence and Assets to Entrench Its Strategy in Allogeneic, Off-the-shelf Donor-derived Gamma Delta (γδ) T Cells Technology for Solid and Liquid Cancers

$GDTC SEC Filings

SEC Form 6-K filed by CytoMed Therapeutics Limited

SEC Form 6-K filed by CytoMed Therapeutics Limited

SEC Form 6-K filed by CytoMed Therapeutics Limited

$GDTC Market Insights

Live Market Insights

CytoMed Therapeutics shares are trading higher after the company announced that its subsidiary, IPSC Depository, acquired the license and certain assets of Cellsafe International for approximately $490,000 to be funded from internal cash resources.

Cytomed Therapeutics, Through Its Wholly Owned Subsidiary, IPSC Depository Acquired The Licence And Certain Assets Of Cellsafe International For A Cash Consideration Of About RM 2.3M Or $490,000 To Be Funded From Internal Cash Resources

Benchmark Reiterates Speculative Buy on CytoMed Therapeutics, Maintains $5 Price Target

Recent Analyst Ratings for
$GDTC

$GDTC
Leadership Updates

$GDTC
Press Releases

$GDTC
Large Ownership Changes

$GDTC
Financials

$GDTC
SEC Filings

$GDTC
Market Insights